Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...

Moderna ( NASDAQ: MRNA) shares snapped six straight sessions of losses, as the stock closed 0.46% higher at $63.93 on ...

Under the EU Clinical Trials Regulation, financial incentives are not allowed for participants under 16 to prevent undue ...

Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.

Shares of Moderna Inc. MRNA inched 0.46% higher to $63.93 Thursday, on what proved to be an all-around positive trading ...

Shares of Moderna Inc. MRNA dropped 0.31% to $63.94 Tuesday, on what proved to be an all-around favorable trading session for ...

The CNBC host said that he has reminded his viewers repeatedly that when the Fed is your “enemy” you should stick to ...

With the approval of Moderna's updated COVID-19 vaccine, doctors are hoping the shots will be available soon and Albertans ...

Discover Moderna's groundbreaking patent for mRNA-based methods to induce a robust immune response against HIV, targeting multiple strains with innovative lipid nanoparticle delivery.

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

People can again order four covid tests per household. The move comes ahead of an expected winter coronavirus wave.

LONDON (Reuters) - Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the Court of ...